THSNA 2024 - Chicago, IL

PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

Workshop Schedule

SATELLITE SYMPOSIA

Host a Satellite Symposium

Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2024 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.

Wed - Apr 03

Thu - Apr 04

Fri - Apr 05

Sat - Apr 06

View Program Details

SATURDAY, APRIL 6

6:30 - 1:00 PM

EVENT/OTHER

REGISTRATION
Chicago Promenade

7:00 - 8:00 AM

SATELLITE SYMPOSIUM

FINDING THE TRUSTED FACTOR: 10 YEARS OF FIX EXPERIENCE ACROSS AGES AND SETTINGS (SPONSORED BY SANOFI)
Chicago Ballroom VI

This presentation highlights a decade of experience (since FDA approval) with a Factor IX therapy, exploring its impact across various age groups and settings. You will hear from clinical experts and a patient as they share insights and experience with an EHL FIX therapy that has been trusted for 10 years.

PARADIGM SHIFTS IN HEMOPHILIA PROPHYLAXIS: PUTTING EVIDENCE INTO PRACTICE (SPONSORED BY CLINICAL CARE OPTIONS, LLC)
Chicago Ballroom IX-X

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Joint Accreditation Statement In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Continuing Medical Education CCO designates this live activity for a maximum of 2. 0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Evaluation: http://www. clinicaloptions. com/HemophiliaChicago2024Eval Slides/Resources: www. clinicaloptions. com/HemophiliaChicago2024Program

8:15 - 9:45 AM

HEMOSTASIS / BASIC SCIENCE

BLEEDING IN HYPERMOBILITY/EHLERS DANLOS
Chair/Organizer: Bobby Lee, Lena Volland
Sheraton Ballroom I-II

8:15

ASSESSMENT AND MANAGEMENT OF BLEEDING IN PEDIATRIC PATIENTS WITH HYPERMOBILITY SYNDROME
NICOLE KENDEL.

8:45

PREGNANCY COMPLICATIONS AND OUTCOMES IN EHLERS DANLOS SYNDROME
ASHLEY BENSON.

9:15

CONTRIBUTION OF PLATELET DYSFUNCTION TO BLEEDING IN EHLERS DANLOS SYNDROME
MARIIA KUMSKOVA.

8:15 - 9:45 AM

LABORATORY

QUALITY IMPROVEMENT EFFORTS IN LABORATORY HEMOSTASIS/THROMBOSIS TESTING
Chair/Organizer: Marian Rollins-Raval, Vinai Bhagirath
Chicago Ballroom VII

8:15

PREANALYTIC VARIABLES -- (UPDATES INCLUDING CLSI)
ANNIE WINKLE.

8:45

FACTOR XIII TESTING- WHAT IS AVAILABLE? WHAT ARE BEST PRACTICES FOR TESTING? EFFECT OF CONCENTRATES ON LAB TESTS? ANTIGEN VERSUS ACTIVITY TESTING? ANY REMAINING ROLE FOR CLOT SOLUBILITY?
NATALIE MATHEWS.

9:15

PLATELET AGGREGATION TESTING IN THROMBOCYTOPENIC PATIENTS
CATHY HAYWARD.

8:15 - 9:45 AM

THROMBOSIS

YOUNG, WILD AND VTE - TREATMENT CONSIDERATIONS FOR ADOLESCENTS AND YOUNG ADULTS
Chair/Organizer: Julie Jaffray, Leo Brandao
Sheraton Ballroom IV-V

8:15

PULMONARY EMBOLUS IN ADOLESCENTS: TREATMENT CHALLENGES AND OPPORTUNITIES
JULIE JAFFRAY.

8:45

CONTINUING "THE PILL" OR NOT?: VTE TREATMENT AND EXOGENOUS HORMONES
MARIE-CLAUDE PELLAND MARCOTTE.

9:15

THE CHANGING LANDSCAPE OF ANTICOAGULATION TREATMENT IN CHILDREN
LAURA AVILA.

9:45 - 10:30 AM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Riverwalk AB

A1. ANTICOAGULATION CLINICS

701

NECESSITY OF ANTI-XA LEVEL MONITORING FOR PROPHYLACTIC ENOXAPARIN IN CHILDREN AND ADOLESCENTS: A SINGLE INSTITUTION EXPERIENCE
RENE GONZALEZ¹, ABIGAIL DAVISON^{1, 2}, SARAH E. SARTAIN^{1, 2}, CLAY T. COHEN^{1, 2}. ¹Texas Children's Hospital, Houston, TX, USA. ²Baylor College of Medicine, Houston, TX, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

703

INSIGHT INTO ATHN 16: TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS TO EVALUATE THE SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW
TAMMUELLA CHRISENTERY-SINGLETON¹, SUCHITRA ACHARYA², SANJAY AHUJA³, LAUREN AMOS⁴, MEERA CHITLUR⁵, MIGUEL ESCOBAR⁶, ASHLEY EASON⁷, SHVETA GUPTA⁸, PHILLIP KURIAKOSE⁹, SHARON PENNINGTON¹⁰, RAJIV PRUTHI¹¹, MICHAEL RECHT¹², SPENCER SULLIVAN¹³, DORIS QUON¹⁴, ALLISON WHEELER¹⁵, MARK REDING¹⁶. ¹American Thrombosis and Hemostasis Network, Rochester, NY, USA. ²Northwell Health Hemostasis and Thrombosis Center, New Hyde Park, NY, USA. ³University Hospitals Health System Cleveland, Cleveland, OH, USA. ⁴Childrena, Kansas City, MO, USA. ⁵Central Michigan University/Childrena, Detroit, MI, USA. ⁶University of Texas Health Science Center, Houston, TX, USA. ⁷Willett Children's Hemophilia Treatment Center at Memorial Health, Savannah, GA, USA. ⁸Arnold Palmer Hospital for Children, Orlando, FL, USA. ⁹Henry Ford Health System, Detroit, MI, USA. ¹⁰Louisiana Center for Advanced Medicine, Slidell, LA, USA. ¹¹Mayo Clinic, Rochester, MN, USA. ¹²National Blood Disorders Foundation, New York, NY, USA. ¹³Mississippi Center for Advanced Medicine, Madison, MS, USA. ¹⁴Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA. ¹⁵Vanderbilt University Medical Center, Nashville, TN, USA. ¹⁶University of Minnesota Medical Center, Minneapolis, MN, USA

704

IMPACT OF MRNA COVID-19 VACCINATION ON D-DIMER LEVELS AND ANTI-PF4 SEROCONVERSION IN HEALTHY ADULTS: A SYSTEMATIC REVIEW
EVAN Y MAROUN M. S. , MEGAN CENTRELLA, GRACE HANSEN, TREVOR FORSBERG, TARIQ RAHAMAN M. L. I. S. , HOANG NGUYEN M. D. PH. D. . Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, USA

705

UTILITY OF THROMBOELASTOGRAPHY VERSUS ROUTINE COAGULATION TESTS: CARDIAC BYPASS SURGERY.
ISABEL RODRIGUEZ MARTIN. Hospital Universitario Virgen del Rocio, SEVILLA, Spain

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

706

CLINICAL OUTCOMES OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA WITH AND WITHOUT PROPHYLAXIS THERAPY: A MULTINATIONAL CHART REVIEW STUDY
PAUL COPPO¹, MARIE SCULLY², JOHANNA A KREMER HOVINGA³, MARIA JOSE ARAGON⁴, PARTH PATWARI⁵, LINDA T WANG⁵, BJAPRN MELLGAYRD⁵, RAGY SAAD⁵. ¹APHP. 6a, Paris, France. ²University College London Hospitals NHS Foundation Trust, London, United Kingdom. ³Department of Hematology and Central Hematology Laboratory, Bern University Hospital, Bern, Switzerland. ⁴HCD Economics, Knutsford, United Kingdom. ⁵Takeda Development Center Americas, Inc, Cambridge, MA, USA

707

THE IMPACT OF MULTIDISCIPLINARY PERINATAL CARE FOR WOMEN WITH BLEEDING DISORDERS
VANESSA GIULIANO¹, NATALYA E. OA¹, SHAMSHAH ARATIA⁷, SHALENE WONG⁷, ALLISON RUPNARAINE, ⁷, REBECCA SAMPAT⁷, FILOMENA MEFFE^{2, 3}, JEFFREY WASSERMANN⁸, JILLIAN M. BAKER^4-6, GRACE TANG⁷, MICHELLE SHOLZBERG^{1, 7, 9, 10}. ¹Department of Medicine, University of Toronto, Toronto, ON, Canada. ²Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada. ³Department of Obstetrics and Gynecology, St. Michaela, Toronto, ON, Canada. ⁴Department of Pediatrics, St. Michaela, Toronto, ON, Canada. ⁵Department of Paediatrics, Division of Haematology-Oncology, The Hospital for Sick Children, Toronto, ON, Canada. ⁶Department of Paediatrics, University of Toronto, Toronto, ON, Canada. ⁷St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. ⁸Department Of Anaesthesia, University of Toronto, Toronto, ON, Canada. ⁹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. ¹⁰Li Ka Shing Knowledge Institute, Toronto, ON, Canada

708

TEMPORAL TRENDS AND PREDICTORS OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
MICHAEL IMEH¹, ANI GVAJAIA¹, CHUKWUNONYE AMAESHI², FIDELIS UWUMIRO³. ¹Lincoln Medical and Mental Health Centre, Bronx, NY, USA. ²Montefiore Medical Centre, Bronx, NY, USA. ³University of Benin Teaching Hospital, Benin, Nigeria

709

DEEP PHENOTYPING REVEALS A HIGH PREVALENCE OF DISTRESSING BLEEDING SYMPTOMS IN PATIENTS WITH HYPERMOBILE EHLERS DANLOS SYNDROME (HEDS) SPECTRUM DISEASE .
ROHITH JESUDAS¹, SARAH MATHENA ², KENNETH L. ZHANG³, CHRISTINA LAUKAITIS^{3, 4}, JENNIFER ANDREWS². ¹St. Jude Childrena, Memphis, TN, USA. ²University of Arizona, Tucson, AZ, USA. ³Carle Illinois College of Medicine, Urbana, IL, USA. ⁴Carle Foundation Hospital, Urbana, IL, USA

710

INDIRECT COMPARISON OF PROPHYLAXIS EFFICACY BETWEEN SIMOCTOCOG ALFA AND EFANESOCTOCOG ALFA IN SEVERE HEMOPHILIA A AND THEIR COST IN THE UNITED STATES
CRAIG M. KESSLER¹, FERNANDO F. CORRALES-MEDINA². ¹Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, DC, USA. ²University of Miami-Miller School of Medicine, and University of Miami-Hemophilia Treatment Center, Miami, FL, USA

711

RISK OF THROMBOSIS IN SGLT2 INHIBITOR-ASSOCIATED ERYTHROCYTOSIS: A MULTI-CENTER PROPENSITY-MATCHED ANALYSIS
MERIC MERICLILER^{1, 2}. ¹Division of Hematology and Medical Oncology, Virginia Commonwealth University Health, Richmond, VA, USA. ²Massey Cancer Center, Richmond, VA, USA

712

HOSPITALIZATION OUTCOMES FROM VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: AN ANALYSIS OF THE NATIONAL INPATIENT SAMPLE DATA FROM 2016 TO 2019
YOUJIN OH, ALEJANDRO VALLEJO, ALEXANDRA SUELDO, LINA JAMES, ANGELO CAPUTI ZUNIGA, AYOBAMI OLAFIMIHAN, EKREM TURK. John H. Stroger Jr Hospital, Chicago, IL, USA

713

ACCURATE MEASUREMENT OF FACTOR VIII ACTIVITY AND INHIBITORS IN THE PRESENCE OF MIM8
WILLIAM PICKERING¹, KARIN NANA WELDINGH², MARY ROBINSON¹, CAROLINE COGSWELL¹, WAN HUI ONG CLAUSEN², MIRELLA EZBAN², VLADY OSTROW³. ¹Labcorp Colorado Coagulation, Englewood, CO, USA. ²Novo Nordisk A/S, SAcborg, Denmark. ³Novo Nordisk Inc, Plainsboro, NJ, USA

714

FIRST REAL-WORLD EXPERIENCE ADMINISTERING ETRANACOGENE DEZAPARVOVEC GENE THERAPY FOR PEOPLE WITH HEMOPHILIA B
MATTHEW RYAN¹, ANDREA B. MILLER¹, PATRICK O'HEARN¹, VIDHI DESAI², NATHAN VISWESHWAR³. ¹Hemophilia Outreach Center, Green Bay, WI, USA. ²CSL Behring, King of Prussia, PA, USA. ³University of South Florida, Tampa, FL, USA

A7. PATHOPHYSIOLOGY OF THROMBOSIS

715

THROMBOSIS RATES AND USE OF THROMBOPROPHYLAXIS AFTER DISCHARGE FROM GYNECOLOGIC CANCER-RELATED SURGERY
LETICIA CAMPOVERDE, ALYSSA MERCADEL, DAN MORGENSTER, ASAAD TRABOLSI, THOMAS PLATE IV, RACHEL KRONENFELD, WEI ZHAO, MATTHEW SCHLUMBRECHT , GERALD SOFF. University of Miami, Miami, FL, USA

A8. ANTITHROMBOTIC THERAPY

716

INCIDENCE OF GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIOVASCULAR PATIENTS TAKING ANTITHROMBOTIC MEDICATIONS WITH PROTON PUMP INHIBITORS
MARK EDWARDS¹, XIAOWEN KONG¹, JACOB KURLANDER¹, SCOTT KAATZ², JAMES B FROEHLICH¹, TWYLLA TASSAVA³, CHRISTOPHER GIULIANO⁴, GEOFFREY D BARNES¹. ¹University of Michigan-Michigan Medicine, Ann Arbor, MI, USA. ²Henry Ford Health- Division of Hospital Medicine, Detroit, MI, USA. ³Trinity Health-Ann Arbor, Ann Arbor, MI, USA. ⁴Ascension- St. John Hospital, Detroit, MI, USA

717

ACCURACY OF A WARFARIN CLINICAL DOSING ALGORITHM ENRICHED WITH GENETIC INFORMATION COMPARED TO THE USE OF CLINICAL ALGORITHM
AMR FAHMI¹, AHMED EL BARDISSY¹, MOHAMED SAAD¹, MOHAMED NABIL¹, LOULIA BADER², MOHAMED KASSEM¹, AHMED MAHFOUZ¹, HAZEM ELEWA². ¹Hamad Medical Corporation, Doha, Qatar. ²College of Pharmacy, QU Health, Qatar University, Doha, Qatar

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

718

SAFETY AND COST-EFFECTIVENESS ANALYSIS OF ANTICOAGULATION THERAPY IN ADULT PATIENTS UNDERGOING EXTRACORPOREAL MEMBRANE OXYGENATION
AMANDA ARENELLA¹, MICHAEL CALLOWAY¹, JOSHUA OH². ¹Department of Health Economics and Outcomes Research, Grifols SSNA, Research Triangle Park, NC, USA. ²University of North Carolina at Charlotte, College of Health and Human Services, Department of Public Health Sciences, Charlotte, NC, USA

719

WHAT IS THE ROLE OF FAMILY HISTORY IN THE MANAGEMENT OF VTE?
AYAN RAMANATHAN¹, ISHAAN DHANESHWAR¹, JOSEPH CAPRINI³, FAKIHA SIDDIQUI², ATUL LADDU¹, JAWED FAREED², KRISH PUNYARTHI¹, RICHA MAHAJAN¹. ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Chicago, IL, USA. ³Northshore University Health System, Evanston, IL, USA

10:30 - 11:30 AM

SHORT TALKS

SHORT TALKS - BLEEDING: OUTCOMES AND PREDICTORS
Chair/Organizer: Bethany Samuelson Bannow, Pooja Vijayvargiya
Sheraton Ballroom I-II

10:30

SOCIAL VULNERABILITY AND HEMOPHILIA CARE AND OUTCOMES
POOJA VIJAYVARGIYA¹, BINH LE², CHRISTINE L. KEMPTON^{1, 3}, VANESSA R. BYAMS², BRANDI DUPERVIL², MEREDITH OAKLEY², STACEY A. FEDEWA^{1, 3}. ¹Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. ²Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. ³Hemophilia of Georgia Center for Bleeding a Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USA

10:45

HEAVY MENSTRUAL BLEEDING MAY BE DRIVEN BY LOCALIZED ENDOMETRIAL COAGULOPATHY
BETHANY T SAMUELSON BANNOW¹, LESLIE MYATT², ALISON EDELMAN². ¹Hemostasis a Thrombosis Center at Oregon Health a Science University, Portland, OR, USA. ²Department of Obstetrics and Gynecology, Oregon Health a Science University, Portland, OR, USA

11:00

AGNOSTIC IDENTIFICATION OF PLASMA BIOMARKERS FOR POSTPARTUM HEMORRHAGE RISK
STEPHANIE E. REITSMA¹, JULIA R. BARSOUM², KIRK C. HANSEN³, MONIKA DZIECIATKOWSKA³, ANDRA H. JAMES⁴, KJERSTI M. AAGAARD⁵, HOMA K. AHMADZIA², ALISA S. WOLBERG¹. ¹Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA. ²Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, The George Washington University School of Medicine and Health Science, Washington, DC, USA. ³Biochemistry and Molecular Genetics, The University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ⁴Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, and Department of Medicine under Hematology, Duke University School of Medicine, Durham, NC, USA. ⁵Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

11:15

INDIVIDUAL PHARMACOKINETIC EVALUATION OF FIXED-SEQUENCE SINGLE-DOSE OCTOCOG ALFA, RURIOCTOCOG ALFA PEGOL, AND EFANESOCTOCOG ALFA IN ADULTS WITH SEVERE HEMOPHILIA A
JANICE M. STABER¹, TOSHKO LISSITCHKOV², ANTHONY CHAN³, ANDREW WILSON⁴, JENNIFER DUMONT⁴, ANNEMIEKE WILLEMZE ⁵. ¹Division of Hematology/Oncology, Department of Pediatrics, Carver College of Medicine, University of Iowa Stead Family Children's Hospital, Iowa City, IA, USA. ²Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria. ³McMaster Childrena, Hamilton, ON, Canada. ⁴Sanofi, Cambridge, MA, USA. ⁵Sanofi, Amsterdam, Netherlands

SHORT TALKS - INSIGHTS ON PLATELET BIOLOGY
Chair/Organizer: Cathy Hayward, Viktor Prifti
Chicago Ballroom VII

10:45

DNA DAMAGE REPAIR INHIBITION: A CATALYST FOR ENHANCED MEGAKARYOPOIESIS AND THROMBOPOIESIS
ROELOF H BEKENDAM^{1, 2}, ANDREW STONE¹, CLEMENTINE PAYNE¹, VIRGINIA CAMACHO¹, ISABELLE BECKER¹, ESTELLE CARMINITA¹, MARIA BARRACHINA¹, KELLIE MACHLUS¹, JOSEPH ITALIANO¹. ¹Vascular Biology Program, Boston Children's Hospital, Boston, MA, USA. ²Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

11:00

NOVEL MECHANISM OF THROMBOSIS AND HEMOSTASIS INVOLVING PLATELET ALPHA-DYSTROGLYCAN
VIKTOR PRIFTI^{1, 2}, ARON A. SHOARA^{2, 3}, REID C. GALLANT⁴, SLADJANA SLAVKOVIC^{2, 3}, KANWAL SINGH³, MARGARET RAND¹, WALTER KAHR⁵, YIMING WANG², HEYU NI^{1, 2, 3}. ¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. ²Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michaela, Toronto, ON, Canada. ³Canadian Blood Services Centre for Innovation, Toronto, ON, Canada. ⁴Department of Medicine, University of Toronto, Toronto, ON, Canada. ⁵Department of Biochemistry, University of Toronto, Toronto, ON, Canada

11:15

UNC9426, A SELECTIVE TYRO3 INHIBITOR, DECREASES HUMAN PLATELET ACTIVATION AND INCREASES SURVIVAL IN A MURINE PULMONARY EMBOLISM MODEL
SAMANTHA JUDD¹, STEPHANIE SPRINGBORN¹, ADAM KIDWELL¹, DEBORAH DERYCKERE², DOUGLAS K. GRAHAM², XIAODONG WANG³, BRIAN BRANCHFORD¹. ¹Versiti Blood Research Institute, Wauwatosa, WI, USA. ²Aflac Cancer and Blood Disorders Center and Children's Healthcare of Atlanta, Atlanta, GA, USA. ³Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

10:30

EVALUATING DIAGNOSTIC ALGORITHMS FOR HEPARIN-INDUCED THROMBOCYTOPENIA USING TWO COMBINED RAPID AUTOMATED ASSAYS
ANNA-LISE BISSOLA^{1, 2}, YI ZHANG^{1, 3}, MADISON CRANSTONE^{2, 4}, DONALD ARNOLD^{1, 2}, ISHAC NAZY^{1, 2}. ¹1. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada. ²Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 3. Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada. ³2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, 4. Department of Statistics and Actuarial Science, University of Waterloo, Hamilton, ON, Canada. ⁴1. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada. ⁵1. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada

SHORT TALKS - THROMBOSIS - SPECIAL POPULATIONS
Chair/Organizer: Gabriela Cesarman-Maus, Giuseppe Maiocco
Sheraton Ballroom IV-V

10:30

RECLASSIFICATION OF ANTIPHOSPHOLIPID ANTIBODY SYNDROME ACCORDING TO THE 2023 ACR/EULAR GUIDANCE IN A PHARMACIST DIRECTED ANTICOAGULATION CLINIC
CATHERINE DEFAZIO¹, LARA HORVATH¹, JENNIFER MORGAN¹, MEAGHAN MURPHY¹, ASHLEY SHTOYKO¹, ELIZABETH PHILLIPS². ¹SUNY Upstate Medical University, Syracuse, NY, USA. ²St. John Fisher University, Wegmans School of Pharmacy, Rochester, NY, USA

10:45

UNDERSTANDING PRIMARY ANTIPHOSPHOLIPID SYNDROME: CORRELATING ANTIPHOSPHOLIPID ANTIBODIES PROFILE AND TITERS WITH THROMBOTIC AND HEMATOLOGICAL ACTIVITY
AMAYA LLORENTE-CHAIVEZ, RODRIGO FIGUEROA-MACNDEZ, GABRIELA A. HERNAINDEZ-MOLINA, ALFONSO OROZCO-COLLAZO . Instituto Nacional de Ciencias MAcdicas y NutriciA³n Salvador ZubirAin, Mexico City, Mexico

11:00

NATIONALLY REPRESENTATIVE DATA ON CO-DIAGNOSIS, MORTALITY AND HEALTHCARE BURDEN OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED COVID-19 PATIENTS: RESULTS FROM THE NATIONAL INPATIENT SAMPLE
GIUSEPPE MAIOCCO¹, KRISH KHURANA², NAREG H. ROUBINIAN³, STEPHANIE BITNER¹, WAQAS AZHAR¹, HAREENA SANGHA⁴, NIKHIL GUPTA⁵, EVAN M. BLOCH⁶, MICHAEL B. STREIFF⁶, AARON A. R. TOBIAN⁶, RUCHIKA GOEL^{1, 6, 7}. ¹Southern Illinois University School of Medicine, Springfield, IL, USA. ²SIU School of Medicine P4P program, Springfield, IL, USA. ³Vitalant Research Institute, San Francisco, CA, USA. ⁴University of Texas Southwestern School of Medicine, Dallas, TX, USA. ⁵Case Western Reserve University School of Medicine, Cleveland, OH, USA. ⁶Johns Hopkins University School of Medicine, Baltimore, MD, USA. ⁷Vitalant Corporate Medical Affairs, Scottsdale, AZ, USA

11:15

HEALTH LITERACY IN PEDIATRIC THROMBOSIS PATIENTS AND PARENTS/CAREGIVERS
ATHENA MANCINI, DENISE BASTAS, SINDI MUKAJ, GINA WONG, LEONARDO R. BRANDAPO, JENNIFER VINCELLI , DIANDRA ROLLAN, M. LAURA AVILA. The Hospital for Sick Children, Toronto, ON, Canada

11:45 - 1:00 PM

PLENARY SESSION

SHARED DECISION MAKING BETWEEN PATIENTS AND CLINICIANS
Chair/Organizer: Leslie Lake, Anne Rose
Sheraton Ballroom IV-V

11:45

HOW CAN CLINICIANS HELP PATIENTS MAKE DECISIONS THAT ALIGN WITH THEIR VALUES?
NADINE SHEHATA.

12:10

SHARED DECISION MAKING WHEN THERE ARE LIMITED DATA - HEMOPHILIA GENE THERAPY
LINDSEY GEORGE.

12:35

PATIENT INVOLVEMENT IN GUIDELINES - THE EXPERIENCE WITH THE ASH PEDIATRIC VTE GUIDELINE
SARA VESELY.